Healthcare -
Biotechnology - NASDAQ - US
$ 1.12
1.82 %
$ 3.3 M
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart CNSP
FINANCIALS
Balance Sheet
CNS Pharmaceuticals, Inc.
| Current Assets | 8.66 M |
| Cash & Short-Term Investments | 6.46 M |
| Receivables | 883 K |
| Other Current Assets | 1.31 M |
| Non-Current Assets | 42.4 K |
| Long-Term Investments | 0 |
| PP&E | 6 K |
| Other Non-Current Assets | 36.4 K |
| Current Liabilities | 2.52 M |
| Accounts Payable | 0 |
| Short-Term Debt | 326 K |
| Other Current Liabilities | 2.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
CNS Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 14.9 M |
| Operating Income | -14.9 M |
| Other Expenses | -44.1 K |
| Net Income | -14.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CNS Pharmaceuticals, Inc.
| Net Income | -14.9 M |
| Depreciation & Amortization | 3.31 K |
| Capital Expenditures | -4.19 K |
| Stock-Based Compensation | 839 K |
| Change in Working Capital | -3.69 M |
| Others | 536 K |
| Free Cash Flow | -17.1 M |
Wall Street Analysts Price Targets
CNS Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for CNSP of $0.5 , with forecasts ranging from
a
low of
$0.5 to a high of $0.5 .
CNSP Lowest Price Target
Wall Street Target
0.5 USD
-55.36%
CNSP Average Price Target
Wall Street Target
0.5 USD
-55.36%
CNSP Highest Price Target
Wall Street Target
0.5 USD
-55.36%
4. DIVIDEND
ANALYSIS
CNSP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CNS Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for treatment of brain malignancies HOUSTON, TX / ACCESS Newswire / April 1, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the full year ended December 31, 2024 and outlined recent corporate and clinical development highlights. "Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition in the shadow of a significant unmet medical need keep us motivated and determined to succeed.
accessnewswire.com
- 2 weeks ago
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
benzinga.com
- 3 weeks ago
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity.
accessnewswire.com
- 3 weeks ago
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market ("NASDAQ"). "As we kick off 2025, the Company has never been fundamentally stronger.
accessnewswire.com
- 1 month ago
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
accessnewswire.com
- 1 month ago
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
accessnewswire.com
- 2 months ago
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H409.
accessnewswire.com
- 2 months ago
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part of the event, Sandra Silberman, MD, PhD, Chief Medical Officer of CNS will give an oral presentation titled, "The Use of Traditional Chemotherapy with Activity In the Treatment of Glioblastoma: Novel Formulations of an Anthracylcine & a Taxane That Appear to Cross the Blood-Brain Barrier," on Thursday, February 20, 2025 at 10:45 AM ET.
accessnewswire.com
- 2 months ago
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
In-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the BIO CEO & Investor Conference being held February 10-11, 2025 in New York, NY. Details of the presentation are as follows: Date: Monday, February 10, 2025 Presentation Time: 1:15 PM ET Location: Royale Room In addition to the presentation, management will be available to conduct one-on-one meetings and conference attendees that would like to schedule a meeting with the Company are encouraged to register through the BIO CEO attendee portal.
accessnewswire.com
- 2 months ago
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
accesswire.com
- 4 months ago
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
accesswire.com
- 4 months ago
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
accesswire.com
- 5 months ago
8. Profile
Summary
CNS Pharmaceuticals, Inc. CNSP
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.3 M
Dividend Yield
0.00%
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Contact
2100 West Loop South, Houston, TX, 77027
https://www.cnspharma.com
IPO
Date
Nov. 8, 2019
Employees
3
Officers
Dr. Donald H. Picker Ph.D.
Chief Science Officer
Mr. Christopher S. Downs CPA, CTP, FP&A
Chief Financial Officer
Dr. Sandra L. Silberman M.D., Ph.D.
Chief Medical Officer
Mr. John Michael Climaco Esq., J.D.
Chief Executive Officer, President & Director
Dr. Waldemar Priebe Ph.D.
Founder